Business Wire

1GLOBAL

7.5.2024 11:01:34 CEST | Business Wire | Press release

Share
freenet Leverages 1GLOBAL eSIM Infrastructure to Launch Own Roaming Service

Germany's largest independent mobile service provider, freenet, has partnered with the global telecommunications network 1GLOBAL to power their new offering, freenet Travel.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240506185419/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

1GLOBAL provides roaming services to 7.5 million freenet customers. (Graphic: Business Wire)

This new product creates immediate added value for freenet customers who plan on visiting other countries. Whether travelling for business or leisure, calculating roaming costs and data usage abroad can often be complex. 1GLOBAL eSIMs offer millions of freenet customers a crucial advantage, enabling seamless mobile internet usage in countries outside the EU while avoiding high roaming charges.

"We are among the few providers worldwide capable of supplying and configuring eSIMs ourselves. Through this partnership, millions of freenet customers can now book various data packages for countries outside the EU, allowing them to communicate cost-effectively during their travels."

- Hakan Koç, founder and CEO of 1GLOBAL

1GLOBAL eSIMs: worry-free travel and minimal roaming charges for freenet users

All freenet customers with eSIM-compatible devices now have access to the service. To install the eSIM on their phone, they simply scan a QR code and follow the onscreen prompts. Once downloaded, a 1GLOBAL eSIM can be used as many times as needed in any of the countries supported by the secure high-speed network.

Users can choose from a variety of tariffs and instantly book a data plan for their desired destination, even if they have no internet connection. They will also benefit from 1GLOBAL’s high-speed 4G/5G network. 1GLOBAL has developed a complete eSIM ecosystem including Remote SIM Provisioning (RSP) and Entitlement Servers, ensuring the highest quality throughout the eSIM deployment lifecycle. Their fully integrable API can be customised and adapted to deliver an outstanding client experience across a wide range of telco products.

"By using 1GLOBAL eSIM capabilities, we are embracing a future-proof, modern technology. This enables us to further expand our positioning around digital lifestyle offerings."

- Salome Andrade Pohl, Head of Digital Lifestyle at freenet

About 1GLOBAL

1GLOBAL provides quick and secure mobile network connectivity in over 160 countries worldwide. 1GLOBAL eSIM technology seamlessly integrates into third-party apps and products, and can be installed on any eSIM-compatible mobile device in less than a minute.

Founded in 2022, 1GLOBAL is the new startup of Hakan Koç, co-founder and former co-CEO of AUTO1 Group. 1GLOBAL acquired a group of telco assets operational since 2006, including an internationally recognised, GSMA-accredited global mobile network. Headquartered in London, with an R&D hub in Lisbon, they have now grown to include over 400 employees across 12 countries and have been granted fully regulated MVNO (mobile virtual network operators) status in nine of them.

www.1global.com

About freenet

Freenet offers a comprehensive portfolio of mobile communications, internet, and TV entertainment services. Customers can find the ideal products for their digital life in approximately 500 freenet stores and online at www.freenet-mobilfunk.de.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240506185419/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye